Wielkopolskie Centrum Onkologii Im. Marii Sklodowskiej-Curie — Clinical Trial Site

35 Registered trials

20 Currently recruiting

Organisation

Wielkopolskie Centrum Onkologii Im. Marii Sklodowskiej-Curie

Location

Poznan, Poland

Identifier

ORG-100040506

Address

Ul. Garbary 15, 61-866, Poland

Departments

#048010: Oddzial Onkologii Klinicznej i Immunoonkologii z Pododdzialem Dziennym i Izba Przyjec
5708:Oddzial Radioterapii i Onkologii Ginekologicznej
N/A
Oddzial Chemioterapii
Oddzial Onkologii Klinicznej i Immunoonkologii z Pododdzialem Dziennym i Izba Przyjec
Oddzial Radioterapii
Oddzial Radioterapii i Onkologii Ginekologicznej
Oddział Chemioterapii
Oddział Onkologii Klinicznej i Immunoonkologii z Pododdziałem Dziennym i Izbą Przyjęć
Oddział Onkologii Klinicznej i Immunoonkologii z Pododziałem Dziennym i Izbą Przyjęć
Oddział Radioterapii i Onkologii Ginekologiczne
Oddział Radioterapii i Onkologii Ginekologicznej
Oddział Radioterapii Onkologicznej I
Odział Radioterapii i Onkologii Ginekologicznej
Oncology
Radiotherapy

Clinical trials at this site (35)

Search interface

Study to assess the efficacy and safety of Rina-S plus standard of care compared to standard of care for maintenance treatment of participan… Pending

2025-522167-15-00 Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC) 5
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B… Recruiting

2025-522255-25-00 Fallopian Tube Neoplasms 5 2026-05-18
A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-021) Recruiting

2023-508047-40-00 Ovarian cancer 5 2026-04-30
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( R… Recruiting

2024-519818-31-01 Endometrial Cancer Advanced, Recurrent, Metastatic, or 5 2026-04-10
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s… Recruiting

2022-501606-35-01 Platinum-sensitive epithelial ovarian, fallopian tube, 11 2024-02-21
A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting

2025-521917-24-00 Treatment-Naïve Recurrent/Metastatic Head and Neck Squa 5 2026-01-21
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting

2024-514822-21-00 Platinum-resistant Ovarian Cancer 5 2025-10-02
A clinical study of MK-1084 with targeted therapy and chemotherapy in people with colorectal cancer (MK-1084-012). Recruiting

2024-517232-22-00 KRAS G12C-mutant, Locally Advanced Unresectable or Meta 5 2025-09-26
Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer… Recruiting

2024-516982-35-00 Ovarian Cancer 5 2025-09-11
A clinical study of sacituzumab tirumotecan and pembrolizumab in people with endometrial cancer (MK-2870-033) Recruiting

2024-519331-42-00 pMMR endometrial carcinoma 5 2025-08-22
A Study to Assess safety and Effectiveness of the Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor an… Recruiting

2024-516162-11-00 Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3 5 2025-07-14
A clinical study of sacituzumab tirumotecan with or without pembrolizumab in people with breast cancer (MK-2870-011) Recruiting

2024-516834-36-00 Locally recurrent unresectable or metastatic TNBC with 5 2025-07-08
Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting

2024-513122-27-00 Unresectable, Locally Advanced or Metastatic HER2 posit 5 2025-06-10
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Colorectal Cancer (CRC) 5 2025-02-10
A trial to learn if volrustomig is safe and efficacious in women and young adults with locally advanced cervical cancer. Recruiting

2023-504374-38-00 Locally advanced cervical cancer 5 2024-04-12
Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib… Recruiting

2023-503708-10-00 Locally advanced or metastatic breast cancer 5 2024-02-20
Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib Recruiting

2024-512982-15-00 BRCA Mutated Ovarian Cancer Patients, Epithelian ovaria 5 2021-06-28
A clinical trial investigating the safety, tolerability, and therapeutic effects of BNT113 in combination with pembrolizumab versus pembroli… Recruiting

2024-512671-12-00 Unresectable head and neck squamous cell carcinoma, met 10 2021-03-05
A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatoce… Recruiting

2023-507689-26-00 Histologically or cytologically confirmed Locoregional 5 2019-10-07
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
A Phase 3 Study of DB-1303 vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Ended

2023-507333-17-00 HER2-low, Hormone Receptor Positive, Metastatic Breast 5 2024-04-15
MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer Ended

2023-504816-14-00 Endometrial cancer 5 2024-03-08
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac… Ended

2022-502046-28-00 HER2-Positive, PIK3CA Mutated, Locally Advanced or Meta 5 2023-12-22